Welcome to our dedicated page for Atlas Energy news (Ticker: CANSF), a resource for investors and traders seeking the latest updates and insights on Atlas Energy stock.
Atlas Energy Corp. (CANSF) generates news that reflects its role as an international upstream oil and gas royalty and streaming company and its evolution from Willow Biosciences Inc. Company announcements have described a significant recapitalisation, the completion of a TSX Venture Exchange listing under the symbol ATLE, and changes to its trading status on U.S. over-the-counter markets.
Earlier news releases issued under Willow Biosciences Inc. provide important background for investors tracking this symbol. Those disclosures cover the sale of Willow’s wholly owned operating subsidiary, the resulting status of Willow as having no active business, and the subsequent reorganization and investment agreement that provided for a private placement, new executive leadership, a reconstituted board of directors, and a name change to Atlas Energy Corp. They also outline the expected transition of the listing from the Toronto Stock Exchange to the TSX Venture Exchange and the use of the TSXV Sandbox program.
More recent communications under the Atlas Energy name highlight the company’s upstream royalty and streaming focus, the initial recapitalisation, and its status as a TSXV Sandbox issuer. News items also describe the voluntary delisting of the company’s common shares from the OTCQB and continued trading on the TSX Venture Exchange and OTC Pink market.
Investors following CANSF-related news can review this history to understand how the business focus shifted from precision fermented ingredients and biomanufacturing under Willow Biosciences to oil and gas royalty and streaming interests under Atlas Energy Corp., as well as how the company’s capital structure and listing venues have changed over time.
Willow Biosciences has successfully completed proof of concept and initiated yeast strain optimization for commercial production of astaxanthin, a potent antioxidant used in various industries. This development aims to meet the growing demand for natural, sustainably produced astaxanthin, currently valued at approximately $US 750 million with an expected growth rate of 8% annually. The company leverages its FutureGrown™ technology platform to produce cost-effective, high-purity astaxanthin. Willow plans to update stakeholders on key milestones and potential partnerships.
Willow Biosciences Inc. (OTCQB: CANSF) announced updates on its cannabigerol (CBG) product, focusing on operational advancements and regulatory progress. The Company is expanding its manufacturing network and expects to produce the first commercial CBG batches in H1 2023. Willow has successfully completed Stage 1 of the Generally Recognized as Safe (GRAS) assessment for its FutureGrown™ CBG and aims to initiate Stage 2 by Q3 2022. The Company has filed 12 patent applications related to cannabinoid production, positioning itself for sustained growth in the biosynthetic market.
Willow Biosciences Inc. (OTCQB: CANSF) reported its second quarter 2022 results, showcasing operational advancements, strong leadership, and robust liquidity with $22.1 million in working capital. The company is progressing with a pharmaceutical partnership and expanding its manufacturing capabilities to support FutureGrown™ CBG production. Highlights include successful toxicological assessments, new manufacturing partnerships, and a consolidation of R&D operations in California. Despite challenges in the cannabinoid market, Willow remains focused on long-term growth and product development.
Willow Biosciences has appointed Dr. Peter Seufer-Wasserthal as Interim President and CEO as of July 17, 2022, following the retirement of Trevor Peters. Dr. Seufer-Wasserthal, previously the Chairman of the Board, aims to lead the company in expanding its product portfolio and forging strategic partnerships. Barbara Munroe has been appointed as Lead Independent Director. Willow's commitment to developing sustainable, high-purity ingredients positions it for growth in the biotech sector, particularly in nutrition, food and beverage, and consumer care markets.
Willow Biosciences Inc. (CANSF) announced significant developments on May 11, 2022. The company entered a Manufacturing Services Agreement with a second Contract Development and Manufacturing Organization (CDMO), enhancing its fermentation production capacity for FutureGrown™ products, including cannabigerol (CBG). In addition, Willow has completed the initial Stage 1 toxicological assessment of FutureGrown™ CBG, indicating it is non-mutagenic, a crucial step towards obtaining Generally Recognized as Safe (GRAS) status in the United States.
Willow Biosciences Inc. (OTCQB: CANSF) announced a live webcast investor presentation on February 3rd, 2022, at 2:00 PM EST. President and CEO Trevor Peters will discuss key business areas and engage with investors through a Q&A session. Interested participants must pre-register for the event through the provided link. An archived version of the presentation will be accessible on the company's website afterward. Willow specializes in sustainable cannabinoid production using its FutureGrown™ platform, aiming to benefit various markets.
Willow Biosciences has announced positive results from its first peer-reviewed study on cannabigerol (CBG), detailing its benefits for skincare. Conducted with Signum Biosciences, the study showcased that Willow's FutureGrown CBG significantly reduces skin inflammation and improves barrier function in a clinical trial involving 20 participants. These findings highlight CBG's promise as a skincare ingredient, outperforming cannabidiol (CBD) in several aspects. The study's publication in the journal Molecules adds credibility to Willow's ongoing research in the cannabinoid industry.
Willow Biosciences reported its financial results for Q3 2021, emphasizing significant operational advancements and strong liquidity with $35.7 million in cash. The company highlighted a >400% increase in production titer for cannabigerol (CBG) and announced the addition of cannabinol (CBN) to its development program. Willow also formed an ESG committee to oversee sustainability efforts. The company aims to secure supply agreements and advance its cannabinoid product portfolio, leveraging favorable regulatory changes and its leading position in the biosynthetic cannabinoid market.
Willow Biosciences (CANSF) provided updates on its operations as of Sept. 21, 2021. The company completed its first commercial fermentation run of CBG in March 2021, increasing production titer by over 400%. CBG samples were delivered to Cellular Goods PLC in July 2021. Willow has also developed a process for producing cannabigerolic acid (CBGA), now available for customer evaluation. However, the company faces a patent infringement claim related to CsPT1, which it states is without merit, as it does not use this enzyme in its processes.
Summary not available.